

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 March 2023 (02.03.2023)



(10) International Publication Number
WO 2023/028456 A1

(51) International Patent Classification:

C07K 14/755 (2006.01) C12N 15/85 (2006.01)
A61P 7/04 (2006.01) A61K 48/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2022/075282

(22) International Filing Date:

22 August 2022 (22.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/236,225 23 August 2021 (23.08.2021) US

(71) Applicant: **BIOVERATIV THERAPEUTICS INC.**

[US/US]; 225 Second Avenue, Waltham, Massachusetts
02451 (US).

(72) Inventors: **MAGHODIA, Ajay**; c/o Bioverativ Therapeu-

tics Inc., 225 Second Avenue, Waltham, Massachusetts
02451 (US). **LIU, Tongyao**; c/o Bioverativ Therapeutics
Inc., 225 Second Avenue, Waltham, Massachusetts 02451
(US). **ZAKAS, Philip**; c/o Bioverativ Therapeutics Inc.,
225 Second Avenue, Waltham, Massachusetts 02451 (US).

(74) Agent: **VELEMA, James H.** et al.; Lathrop GPM LLP, 28

State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: OPTIMIZED FACTOR VIII GENES

(57) Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.

WO 2023/028456 A1